Companies Puma Biotechnology, Inc
Puma Biotechnology (PBYI): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Puma Biotechnology, Inc’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers42nd pct.Of 12 peer CEOs
CEO pay, last three years
- $2,944,748FY2023
- $3,969,931FY2024
- $3,062,337FY2025
CEO total pay was $3,062,337 in fiscal 2025, down from $3,969,931 in fiscal 2024.
FY2025: salary $931,333 · stock awards $551,549 · option awards $535,513
Executives and directors
Alan Auerbach · CEODouglas Hunt · ExecutiveMaximo Nougues · CFOJeff Ludwig · CCOAdrian M. Senderowicz, M.D · Independent DirectorAlessandra Cesano, M.D., Ph.D · Independent DirectorAllison Dorval · Independent DirectorBrian Stuglik, R.Ph · Independent DirectorJay M. Moyes · Lead Independent DirectorMichael P. Miller · Independent DirectorTroy E. Wilson, Ph.D., J.D · Independent Director
Frequently asked questions
Who was the highest-paid executive at Puma Biotechnology, Inc in fiscal 2025?
As disclosed, Alan Auerbach (President and Chief Executive Officer) was the highest-paid executive at Puma Biotechnology, Inc in fiscal 2025, with total compensation of $3,062,337.
How does Puma Biotechnology, Inc's chief executive pay compare to its disclosed peer group?
As disclosed, Alan Auerbach's total compensation ranked at the 42nd percentile of Puma Biotechnology, Inc's disclosed peer group.
What is Puma Biotechnology, Inc's CEO-to-median employee pay ratio?
As disclosed, Puma Biotechnology, Inc's CEO-to-median employee pay ratio was 11:1.
How much does Puma Biotechnology, Inc spend in total on board compensation for fiscal 2025?
As disclosed, Puma Biotechnology, Inc reported total board compensation of $1,146,560 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Alan Auerbach | $931,333 | — | $551,549 | $535,513 | $1,027,307 | — | $16,635 | $3,062,337 |
| President and Chief Executive Officer | ||||||||
| Jeff Ludwig | 264,880 | — | 132,998 | 129,131 | — | — | 949,159 | 1,476,167 |
| Chief Commercial Officer | ||||||||
| Maximo Nougues | 562,961 | 130,607 | 170,848 | 165,881 | 191,069 | — | 19,849 | 1,241,215 |
| Chief Financial Officer | ||||||||
| Douglas Hunt | 489,060 | 122,265 | 133,765 | 129,878 | 165,987 | — | 20,445 | 1,061,400 |
| Chief Regulatory Affairs, Medical Affairs, and Pharmacovigilance Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Alan Auerbach | $3,062,337 | $3,969,931 | $2,944,748 | ↓ −907,594 |
| Jeff Ludwig | 1,476,167 | 1,228,288 | 1,381,848 | ↑ +247,879 |
| Maximo Nougues | 1,241,215 | 1,404,978 | 1,231,826 | ↓ −163,763 |
| Douglas Hunt | 1,061,400 | 1,217,501 | 1,021,553 | ↓ −156,101 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program is structured to attract, motivate and retain highly qualified executives by paying them competitively, consistent with our success and their contribution to that success.
| CEO STI target (% of salary) | 65% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Alan Auerbach | RSU | 2025-02-07 | — | — | 198,399 | — | $551,549 |
| Jeff Ludwig | RSU | 2025-02-07 | — | — | 47,841 | — | 132,998 |
| Maximo Nougues | RSU | 2025-02-07 | — | — | 61,456 | — | 170,848 |
| Douglas Hunt | — | 2025-02-07 | — | — | 48,117 | — | 133,765 |
| Jeff Ludwig | OPTION | 2025-02-07 | — | — | 66,221 | — | 129,131 |
| Maximo Nougues | OPTION | 2025-02-07 | — | — | 85,067 | — | 165,881 |
| Douglas Hunt | OPTION | 2025-02-07 | — | — | 66,604 | — | 129,878 |
| Alan Auerbach | OPTION | 2025-02-07 | — | — | 274,622 | — | 535,513 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Alan Auerbach | $551,549 | $0 | $535,513 | 0.0% |
| Jeff Ludwig | 132,998 | 0 | 129,131 | 0.0% |
| Maximo Nougues | 170,848 | 0 | 165,881 | 0.0% |
| Douglas Hunt | 0 | 0 | 129,878 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Alan Auerbach | RSU | 1,645 | — | $9,788 |
| Alan Auerbach | Option | 2,262 | 5 | — |
| Douglas Hunt | RSU | 9,474 | — | 56,370 |
| Maximo Nougues | RSU | 10,827 | — | 64,421 |
| Douglas Hunt | Option | 13,113 | 6.36 | — |
| Maximo Nougues | Option | 14,987 | 6.36 | — |
| Jeff Ludwig | RSU | 23,510 | — | 71,706 |
| Douglas Hunt | RSU | 36,088 | — | 214,724 |
| Alan Auerbach | RSU | 40,199 | — | 239,184 |
| Douglas Hunt | RSU | 43,010 | — | 142,792 |
| Maximo Nougues | RSU | 46,092 | — | 274,247 |
| Douglas Hunt | Option | 49,953 | 2.78 | — |
| Maximo Nougues | RSU | 51,669 | — | 171,734 |
| Alan Auerbach | Option | 55,644 | 6.36 | — |
| Jeff Ludwig | RSU | 55,882 | — | 170,441 |
| Maximo Nougues | Option | 63,801 | 2.78 | — |
| Alan Auerbach | RSU | 148,800 | — | 885,360 |
| Alan Auerbach | RSU | 179,886 | — | 598,031 |
| Alan Auerbach | Option | 205,967 | 2.78 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Jay M. MoyesIndependent · Lead Independent Director · Audit (Chair) · Compensation | $77,500 | $95,580 | $0 | — | $0 | $173,080 |
| Troy E. Wilson, Ph.D., J.DIndependent · Audit · Nominating/Governance (Chair) · Research and Development | 77,500 | 95,580 | 0 | — | 0 | 173,080 |
| Brian Stuglik, R.PhIndependent · Compensation (Chair) · Research and Development | 72,500 | 95,580 | 0 | — | 0 | 168,080 |
| Adrian M. Senderowicz, M.DIndependent · Nominating/Governance · Research and Development (Chair) | 70,000 | 95,580 | 0 | — | 0 | 165,580 |
| Michael P. MillerIndependent · Compensation · Nominating/Governance | 62,500 | 95,580 | 0 | — | 0 | 158,080 |
| Allison DorvalIndependent · Audit | 60,000 | 95,580 | 0 | — | 0 | 155,580 |
| Alessandra Cesano, M.D., Ph.DIndependent · Research and Development | 57,500 | 95,580 | 0 | — | 0 | 153,080 |
| Alan H. AuerbachEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $300,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | each non-employee director is expected to attain beneficial ownership of 10,000 shares of our common stock no later than April 2022, and to maintain or exceed such ownership throughout service |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $477,500 |
| Equity awards (grant-date value) | $669,060 |
| All other compensation | $0 |
| Total cost of the board | $1,146,560 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Puma Biotechnology as a peer
Companies that benchmark against PBYI
8 companies name PBYI as a compensation peer
The list of companies that name PBYI as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
KPTI Karyopharm TherapeuticsAKBA Akebia TherapeuticsASRT Assertio Holdings, Inc.MGNX MacroGenics, Inc.NKTR Nektar TherapeuticsESPR Esperion TherapeuticsRIGL Rigel PharmaceuticalsORGO Organogenesis HoldingsCHRS Coherus BioSciencesACRS Aclaris TherapeuticsHRTX Heron TherapeuticsAGEN Agenus Inc.
Peer reciprocity
The companies Puma Biotechnology, Inc names as compensation peers that name it back in their own disclosed peer groups.
Akebia Therapeutics (AKBA)57Esperion Therapeutics (ESPR)58Rigel Pharmaceuticals (RIGL)59Coherus BioSciences (CHRS)60
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Organogenesis Holdings | 2025 | Gary Gillheeney | $979,105 | $2,833,330 | $1,380,017 | $1,536,575 | $6,811,754 |
| 2 | Nektar Therapeutics | 2025 | Howard Robin | 1,106,282 | 942,081 | 2,986,535 | 1,106,282 | 6,256,954 |
| 3 | Akebia Therapeutics | 2025 | John Butler | 864,010 | 2,164,338 | 2,024,798 | 580,973 | 5,652,339 |
| 4 | Rigel Pharmaceuticals | 2025 | Raul Rodriguez | 787,405 | 951,327 | 2,241,570 | 634,649 | 4,658,805 |
| 5 | Esperion Therapeutics | 2025 | Sheldon Koenig | 770,833 | 1,260,000 | 847,929 | 639,375 | 3,535,512 |
| 6 | Heron Therapeutics | 2025 | Craig Collard | 689,431 | 946,254 | 1,352,917 | 517,189 | 3,516,291 |
| 7 | Aclaris Therapeutics | 2025 | Neal Walker | 615,000 | 828,426 | 1,581,615 | 350,550 | 3,375,591 |
| 8 | Puma Biotechnology, Inc | 2025 | Alan Auerbach | 931,333 | 551,549 | 535,513 | 1,027,307 | 3,062,337 |
| 9 | Coherus BioSciences | 2025 | Dennis Lanfear | 1,026,545 | 0 | 828,130 | 869,295 | 2,736,874 |
| 10 | Karyopharm Therapeutics | 2025 | Richard Paulson | 770,000 | 838,996 | 241,544 | 350,350 | 2,320,902 |
| 11 | MacroGenics, Inc. | 2025 | Eric Risser | 561,568 | 52,000 | 1,049,386 | 251,900 | 2,078,854 |
| 12 | Assertio Holdings, Inc. | 2025 | Mark Reisenauer | 202,060 | 458,093 | 784,425 | 0 | 1,449,996 |
| 13 | Agenus Inc. | 2025 | Garo Armen | 715,260 | 0 | 141,000 | 0 | 1,350,325 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Puma Biotechnology, Inc | 169.7% | Options 50 · RSU 50 | not disclosed | Compensia |
| Aclaris Therapeutics | not disclosed | not disclosed | not disclosed | Pearl Meyer |
| Agenus Inc. | 125% | Options 100 | not disclosed | Aon Radford |
| Akebia Therapeutics | 90% | Options 50 · RSU 25 · MSU 25 | No | Pearl Meyer |
| Assertio Holdings, Inc. | not disclosed | RSU 50 · Option 50 | not disclosed | Pearl Meyer |
| Coherus BioSciences | not disclosed | Option 100 | not disclosed | Aon |
| Esperion Therapeutics | 110% | not disclosed | not disclosed | not disclosed |
| Heron Therapeutics | not disclosed | Option 66.67 · RSU 33.33 | not disclosed | Compensia, Inc. |
| Karyopharm Therapeutics | 90% | not disclosed | Yes — Relative TSR | Alpine, WTW |
| MacroGenics, Inc. | 85% | not disclosed | not disclosed | Alpine Rewards, LLC |
| Nektar Therapeutics | 100% | not disclosed | No | Aon |
| Organogenesis Holdings | not disclosed | not disclosed | not disclosed | Pearl Meyer |
| Rigel Pharmaceuticals | 124% | Options 75 · RSU 25 | No | Pearl Meyer |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
CEO pay ratio
| Ratio (CEO : median employee) | 11 : 1 |
|---|---|
| CEO total compensation | $3,062,337 |
| Median employee compensation | $273,504 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Allison Dorval | Director | 2026-06-11 | A | 27,000 | $0 | $0 | Common | Form 4 ↗ |
| Jay M. Moyes | Director | 2026-06-11 | A | 27,000 | 0 | 0 | Common | Form 4 ↗ |
| Adrian Senderowicz | Director | 2026-06-11 | A | 27,000 | 0 | 0 | Common | Form 4 ↗ |
| Brian M. Stuglik | Director | 2026-06-11 | A | 27,000 | 0 | 0 | Common | Form 4 ↗ |
| Michael P. Miller | Director | 2026-06-11 | A | 27,000 | 0 | 0 | Common | Form 4 ↗ |
| Alessandra Cesano | Director | 2026-06-11 | A | 27,000 | 0 | 0 | Common | Form 4 ↗ |
| Troy Edward Wilson | Director | 2026-06-11 | A | 27,000 | 0 | 0 | Common | Form 4 ↗ |
| Jay M. Moyes | Director | 2026-06-12 | D | 22,000 | 7 | 158,796 | Common | Form 4 ↗ |
| Brian M. Stuglik | Director | 2026-06-12 | D | 8,100 | 7 | 58,311 | Common | Form 4 ↗ |
| Troy Edward Wilson | Director | 2026-06-12 | D | 10,800 | 7 | 77,748 | Common | Form 4 ↗ |
| Allison Dorval | Director | 2026-06-12 | D | 11,610 | 7 | 83,579 | Common | Form 4 ↗ |
| Adrian Senderowicz | Director | 2026-06-12 | D | 27,000 | 7 | 194,311 | Common | Form 4 ↗ |
| Maximo Nougues | Chief Financial Officer | 2026-07-06 | D | 9,386 | 8 | 77,557 | Common | Form 4 ↗ |
| Alan H. Auerbach | Director | 2026-07-06 | D | 44,058 | 8 | 364,051 | Common | Form 4 ↗ |
| Douglas Hunt | See Remarks | 2026-07-06 | D | 8,460 | 8 | 69,905 | Common | Form 4 ↗ |
| Alessandra Cesano | Director | 2026-09-14 | D | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Alessandra Cesano | Director | 2026-09-14 | D | 62,150 | 9 | 566,994 | Common | Form 4 ↗ |
| Alessandra Cesano | Director | 2026-09-14 | A | 50,000 | 3 | 146,500 | Common | Form 4 ↗ |
| Troy Edward Wilson | Director | 2026-09-14 | D | 5,000 | 9 | 45,500 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (60 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Alan Auerbach. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table” · page 26. As printed: 3,062,337. View filing ↗
- Section 01, Jeff Ludwig. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table” · page 26. As printed: 1,476,167. View filing ↗
- Section 01, Maximo Nougues. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table” · page 26. As printed: 1,241,215. View filing ↗
- Section 01, Douglas Hunt. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table” · page 26. As printed: 1,061,400. View filing ↗
- Section 03, Alan Auerbach RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Jeff Ludwig RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Maximo Nougues RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Douglas Hunt . DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Jeff Ludwig OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Maximo Nougues OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Douglas Hunt OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Alan Auerbach OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-28. Section “CEO Pay Ratio”. As printed: 11 : 1. View filing ↗
- Section 08, Jay M. Moyes. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 173,080. View filing ↗
- Section 08, Troy E. Wilson, Ph.D., J.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 173,080. View filing ↗
- Section 08, Brian Stuglik, R.Ph. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 168,080. View filing ↗
- Section 08, Adrian M. Senderowicz, M.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 165,580. View filing ↗
- Section 08, Michael P. Miller. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 158,080. View filing ↗
- Section 08, Allison Dorval. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 155,580. View filing ↗
- Section 08, Alessandra Cesano, M.D., Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 153,080. View filing ↗
- Section 08, Alan H. Auerbach. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Allison Dorval 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jay M. Moyes 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adrian Senderowicz 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian M. Stuglik 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael P. Miller 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alessandra Cesano 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Troy Edward Wilson 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jay M. Moyes 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian M. Stuglik 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Troy Edward Wilson 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allison Dorval 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adrian Senderowicz 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Maximo Nougues 2026-07-06. Form 4, filed 2026-07-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alan H. Auerbach 2026-07-06. Form 4, filed 2026-07-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Douglas Hunt 2026-07-06. Form 4, filed 2026-07-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alessandra Cesano 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alessandra Cesano 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alessandra Cesano 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Troy Edward Wilson 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 477,500 + equity 669,060 + all other 0 = 1,146,560, summed across the director compensation table rows.
- Organogenesis Holdings, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Organogenesis Holdings's own proxy. As printed: 6,811,754. View filing ↗
- Nektar Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Nektar Therapeutics's own proxy. As printed: 6,256,954. View filing ↗
- Akebia Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Akebia Therapeutics's own proxy. As printed: 5,652,339. View filing ↗
- Rigel Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Rigel Pharmaceuticals's own proxy. As printed: 4,658,805. View filing ↗
- Esperion Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Esperion Therapeutics's own proxy. As printed: 3,535,512. View filing ↗
- Heron Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Heron Therapeutics's own proxy. As printed: 3,516,291. View filing ↗
- Aclaris Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Aclaris Therapeutics's own proxy. As printed: 3,375,591. View filing ↗
- Puma Biotechnology, Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Puma Biotechnology, Inc's own proxy. As printed: 3,062,337. View filing ↗
- Coherus BioSciences, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in Coherus BioSciences's own proxy. As printed: 2,736,874. View filing ↗
- Karyopharm Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Karyopharm Therapeutics's own proxy. As printed: 2,320,902. View filing ↗
- MacroGenics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in MacroGenics, Inc.'s own proxy. As printed: 2,078,854. View filing ↗
- Assertio Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Assertio Holdings, Inc.'s own proxy. As printed: 1,449,996. View filing ↗
- Agenus Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Agenus Inc.'s own proxy. As printed: 1,350,325. View filing ↗
- Section 10a, Akebia Therapeutics reciprocity. DEF 14A. Akebia Therapeutics names Puma Biotechnology, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Esperion Therapeutics reciprocity. DEF 14A. Esperion Therapeutics names Puma Biotechnology, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Rigel Pharmaceuticals reciprocity. DEF 14A. Rigel Pharmaceuticals names Puma Biotechnology, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Coherus BioSciences reciprocity. DEF 14A. Coherus BioSciences names Puma Biotechnology, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗